13.08.2024 | Colorectal Cancer
Understanding Quality of Life After Pelvic Exenteration for Patients with Rectal Cancer
verfasst von:
Kilian G. M. Brown, MBBS, BBiomed, MPhil, FRACS, Michael J. Solomon, MB, BCH, (Hons), BAO, MSc, DMedSc, DMed, FRCSI, FRACS, FASCRS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2024
Einloggen, um Zugang zu erhalten
Auszug
As recently as the 1990s, pelvic exenteration for rectal cancer was associated with substantial morbidity and a perioperative mortality rate of up to 20%, the survival benefit was not well demonstrated, and there was essentially no quality of life (QOL) data. With these poor outcomes, pelvic exenteration has historically not been widely accepted by the surgical community. In 2024, pelvic exenteration is now established as the standard of care for appropriately selected patients with locally advanced primary and recurrent rectal cancer. The pioneering period of the 1990s and 2000s, in which demonstration of safety and oncological feasibility was the priority, is now well behind us. The clinical and academic focus at specialist units around the globe is now on further improvement of the encouraging oncological and QOL outcomes reported in recent decades, as well as minimizing postoperative complications, in pursuit of excellence. …
